ArticleDiscover oncology2025
Identifying key genes involved in HBV-related hepatocellular carcinoma: diagnose, prognosis, interaction and immune analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatitis B virus associated hepatocellular carcinoma (HBV-HCC) have been a serious global health problem. This study aimed to uncover the key genes in HBV-HCC, and clarity their function, interaction, diagnostic and prognostic value, impacts on immune infltration and potential drugs targeting these genes.
methodsFour gene expression datasets totally containing 117 paired tumor tissues and adjacent control tissues were selected from the GEO database and used to screen the differentially expressed genes (DEGs). Function analysis were performed by using GO and KEGG enrichment. STRING and cytoscape were used to analyze protein-protein interaction (PPI) and screen hub gene. Survival analysis and receiver operator characteristic (ROC) curve were used to explore the prognostic and diagnostic value of key genes. Immune infiltration analysis were performed by CIBERSORT algorithm. Drug-Gene Interaction Database (DGIdb) was used to screen the potential drug that affect hub genes.
resultsOverall, 234 shared DEGs were screened from four GSE datasets, which were mainly enrichment in cell growth regulation, epoxygenase P450 pathway, cellular response to multiple ion, xenobiotic metabolic process and complement activation. Six hub genes (HMMR, NDC80, CDK1, EZH2, ESR1, FOXM1) were screen by PPI analysis. ESR1 was down-regulated and associated with favorable prognosis in HBV-HCC, while HMMR, NDC80, CDK1 and EZH2 were up-regulated and correlation with shorter overall survival. Furthermore, ROC analysis and nomogram demonstrated the high diagnostic performance of NDC80, CDK1 and EZH2. Immune infiltration analysis showed that there were significant difference of several immune cell types between tumor and control tissues, including T cells, monocyte/macrophage and dendritic cells. There were significant correlation between hub genes with immune infiltration. Finally, DGIdb analysis showed there were several approved or new drugs that interaction with HMMR, CDK1, ESR1 and EZH2.
conclusionSix hug-genes are closely related to the HBV-HCC development, which involved in multiple biological progress and immune infiltration. Among them, NDC80, CDK1, EZH2 could severed as markers with good diagnostic and prognostic value. Notably, several approved drugs interaction with hub genes might be potential drug used for HBV-HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.